Is IDEAYA Biosciences (IDYA) A Bargain After New ESMO Trial Data?

Simply Wall St.10-25

IDEAYA Biosciences (IDYA) is back in focus after new Phase 1 data for IDE849 in relapsed small cell lung cancer and other neuroendocrine tumors landed at ESMO 2026, highlighting updated survival and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2678188017?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-25 01:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2678188017","market":"sg","top_or_hot":-1,"title":"Is IDEAYA Biosciences (IDYA) A Bargain After New ESMO Trial Data?","media":"Simply Wall St.","content":"<div>\n<p>IDEAYA Biosciences (IDYA) is back in focus after new Phase 1 data for IDE849 in relapsed small cell lung cancer and other neuroendocrine tumors landed at ESMO 2026, highlighting updated survival and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-ideaya-biosciences-idya-a-bargain-after-new-esmo-trial-da\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is IDEAYA Biosciences (IDYA) A Bargain After New ESMO Trial Data?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs IDEAYA Biosciences (IDYA) A Bargain After New ESMO Trial Data?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-25 01:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-ideaya-biosciences-idya-a-bargain-after-new-esmo-trial-da><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IDEAYA Biosciences (IDYA) is back in focus after new Phase 1 data for IDE849 in relapsed small cell lung cancer and other neuroendocrine tumors landed at ESMO 2026, highlighting updated survival and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-ideaya-biosciences-idya-a-bargain-after-new-esmo-trial-da\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-ideaya-biosciences-idya-a-bargain-after-new-esmo-trial-da","article_id":"2678188017","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-ideaya-biosciences-idya-a-bargain-after-new-esmo-trial-da","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2678188017","pubTimestamp":1792862877,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"IDEAYA Biosciences (IDYA) is back in focus after new Phase 1 data for IDE849 in relapsed small cell lung cancer and other neuroendocrine tumors landed at ESMO 2026, highlighting updated survival and safety outcomes.\nIDEAYA Biosciences shares have been choppy around the recent ESMO news, with the 1-day share price return down 3.9% and the 30-day share price return down 7.34%. However, the 1-year total shareholder return of 18.95% and 5-year total shareholder return of 61.89% suggest longer...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IDYA":"IDEAYA Biosciences","BK4139":"生物科技"},"translate_title":"新的 ESMO 试验数据公布后，IDEAYA Biosciences (IDYA) 是否便宜？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"IDYA":1.5},"content_text":"IDEAYA Biosciences (IDYA) is back in focus after new Phase 1 data for IDE849 in relapsed small cell lung cancer and other neuroendocrine tumors landed at ESMO 2026, highlighting updated survival and safety outcomes. IDEAYA Biosciences shares have been choppy around the recent ESMO news, with the 1-day share price return down 3.9% and the 30-day share price return down 7.34%. However, the 1-year total shareholder return of 18.95% and 5-year total shareholder return of 61.89% suggest longer term holders have still seen meaningful gains as sentiment swings with each clinical update. Scan other precision-oncology opportunities moving on fresh trial data with a curated set of 34 healthcare AI stocks aligned to themes similar to IDEAYA Biosciences. IDEAYA Biosciences has pulled back on strong IDE849 and darovasertib updates, so the debate now is simple: Is the bigger opportunity still ahead, or did most of the upside already play out in the past year’s run and volatility? AdvertisementMost Popular Narrative: 34% Undervalued Analysts following IDEAYA Biosciences see a gap between the last close at $34.71 and a narrative fair value of $52.75, and that gap rests heavily on how the pipeline translates into durable oncology franchises over time.  The main factor that needs to go right is successful execution on multiple registrational programs, including darovasertib in uveal melanoma and IDE849 in extensive-stage small-cell lung cancer, while managing trial pivots and competitive pressure in DLL3 therapies. The current valuation implies that the market is not fully crediting IDEAYA Biosciences for the potential of darovasertib, the MTAP/CDKN2A/KRAS franchise, the DLL3 Topo-ADC program, and a cash balance of about US$1.24b with a stated runway into 2030.  See why 1 investors see IDEAYA Biosciences as 34% undervalued. Result: Fair Value of $52.75 (UNDERVALUED) Still, two pressure points could upend the IDEAYA Biosciences bull case, including any delay to darovasertib approvals and weaker than expected IDE849 differentiation in the crowded DLL3 therapy space. Find out about the key risks to this IDEAYA Biosciences narrative. Another View: SWS DCF Model Flags Overvaluation While the popular narrative pegs IDEAYA Biosciences at a fair value of $52.75, the SWS DCF model points in the opposite direction. On this framework, IDEAYA Biosciences screens as overvalued, with an estimated future cash flow value of $20.76 against the current $34.71 share price. That sort of gap raises a simple question for you as an investor: Which story feels more realistic for how cash generation might actually evolve over time? Look into how the SWS DCF model arrives at its fair value. IDYA Discounted Cash Flow as at Oct 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 27 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Mixed messages around IDEAYA Biosciences can feel confusing, so review the key data points promptly and anchor your own stance with 1 key reward and 1 important warning sign. Looking for more IDEAYA Biosciences style investment ideas? If IDEAYA Biosciences has your attention, do not stop here. Use focused screeners to surface fresh candidates before they move and sharpen your watchlist.  Target steady cash generators and stress test your income focus with a curated set of 5 dividend fortresses that may suit a yield oriented approach. Hunt for potential mispricings and widen your opportunity set by scanning a tailored pool of 21 high quality undiscovered gems before they land on everyone else's radar. Prioritise resilience and sleep easier at night by filtering the market for a 30 resilient stocks with low risk scores that fits your comfort with volatility and downside.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2678188017","isCrawlerRequest":true}